A Phase 1 interventional study of Enantyum® oral solution and Keral® tablet in Acute Pain, sponsored by Menarini Group. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-09.
Sponsored by Menarini Group · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Acute Pain with a site in United Kingdom — 2 open to participants now, 2 under way, none of them phase 3. Acute Pain · United Kingdom.
Among the 13 studies in Acute Pain with a site in United Kingdom, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2014, is one of 2 in phase 1, and was the 3rd registered.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
Browse Acute Pain studies →2 of the 13 studies in Acute Pain with a site in United Kingdom are open now. Recruiting first, the newest first:
Newcastle University · Sites in United Kingdom
Ages up to 37 wk
York University · Sites in United Kingdom, Canada
Ages 25 wk–33 wk
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 127 across the 10 interventional studies, 389 across the 3 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 10 most frequent:
Menarini Group is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Menarini Group has 4 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Acute Pain with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the bioavailability of 25 mg DKP.TRIS given as an Enantyum® oral solution (Test formulation) and Keral® tablet (Reference formulation). In addition, this study intends to evaluate the safety and tolerability of Test and Reference formulations.
The study was conducted in 1 site and included 26 successfully screened and randomized healthy subjects(12 female and 14 male).
The study consisted of:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25mg DKP.TRIS oral solution
Drug: Enantyum® oral solution
25mg DKP.TRIS tablet
Drug: Keral® tablet
One dose of 25 mg DKP oral solution
One dose of 25 mg DKP tablet
Cmax
The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 133.00% for Cmax.
Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
AUC(0-t)
The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 125.00% for AUC(0-t).
Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
AUC(0-∞)
AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively.
Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
Tmax
AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax).
Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
t1/2
AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively.
Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
| Milestone | Reference IMP First, Then Test IMP | Test IMP First, Then Reference IMP |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 13 |
| Not completed | 0 | 0 |
| Milestone | Reference IMP First, Then Test IMP | Test IMP First, Then Reference IMP |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 13 |
| Not completed | 0 | 0 |
| Milestone | Reference IMP First, Then Test IMP | Test IMP First, Then Reference IMP |
|---|---|---|
| Started | 13 | 13 |
| Completed | 12 | 13 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 133.00% for Cmax.
| ng/mL | Enantyum® Oral Solution | Keral® Tablet |
|---|---|---|
| Cmax | 3290.70 (2996.00 to 3614.40) | 2785.90 (2493.20 to 3113.00) |
AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively.
| h*ng/mL | Enantyum® Oral Solution | Keral® Tablet |
|---|---|---|
| AUC(0-∞) | 3473.00 (3087.70 to 3906.40) | 3485.60 (3135.30 to 3875.00) |
The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 125.00% for AUC(0-t).
| h*ng/mL | Enantyum® Oral Solution | Keral® Tablet |
|---|---|---|
| AUC(0-t) | 3362.20 (2986.20 to 3785.60) | 3372.00 (3027.30 to 3755.90) |
AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax).
| h | Enantyum® Oral Solution | Keral® Tablet |
|---|---|---|
| Tmax | 0.25 (0.17 to 0.67) | 0.50 (0.25 to 1.25) |
AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively.
| h | Enantyum® Oral Solution | Keral® Tablet |
|---|---|---|
| t1/2 | 1.34 (1.23 to 1.45) | 1.30 (1.20 to 1.41) |
Collected over from Screening Visit to End of Study Visit. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enantyum® Oral Solution | — | 0/25 (0%) | 4/25 (16%) |
| Keral® Tablet | — | 0/26 (0%) | 7/26 (26.9%) |
| Event | Enantyum® Oral Solution | Keral® Tablet |
|---|---|---|
| Hepatic enzyme increasedInvestigations | 1/25 | 0/26 |
| Serum ferritin decreasesInvestigations | 1/25 | 0/26 |
| HeadacheNervous system disorders | 1/25 | 1/26 |
| SyncopeNervous system disorders | 1/25 | 0/26 |
| Abdominal pain upperGastrointestinal disorders | 0/25 | 1/26 |
| PresyncopeNervous system disorders | 0/25 | 1/26 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/25 | 1/26 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/25 | 1/26 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/25 | 1/26 |
| SneezingRespiratory, thoracic and mediastinal disorders | 0/25 | 1/26 |
Twenty-six (26) subjects were randomized (14 male and 12 female) for 24 to complete the study. A total of 25 subjects (13 male and 12 female) completed the study. NOTE: Treatments were administered in a crossover manner, with the same population but one healthy subjects being exposed to the Reference and Test IMP.
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 28.9 ± 6.39 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 12 |
| Male | 14 |
| Region of Enrollment(participants) | Entire Study Population |
|---|---|
| United Kingdom | 26 |
The record gives a start of Apr 2014, a primary completion of May 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexketoprofen